Literature DB >> 9219008

Penetrance of familial hypertrophic cardiomyopathy.

P Charron1, L Carrier, O Dubourg, F Tesson, M Desnos, P Richard, G Bonne, P Guicheney, B Hainque, J B Bouhour, A Mallet, J Feingold, K Schwartz, M Komajda.   

Abstract

Familial hypertrophic cardiomyopathy (FHC) is an autosomal dominant cardiac disease for which the penetrance remains a much-debated issue. Since the recent identification of the genes involved in the disease, the penetrance of FHC has not been reassessed in a large genotyped population. The aim of our study was therefore to evaluate it, according to age and sex, in ten families with previously identified mutations. Among 178 individuals we studied, 90 were genetically affected (9 different mutations in 3 genes). We found that penetrance, assessed by classical echocardiographic and electrocardiographic criteria, was (1) incomplete: 69%; (2) age-related: 55% between 10 and 29 years old, 75% between 30 and 49 y. and 95% over 50 y.; (3) greater in males than in females: 77% vs 58%, age-adjusted odds ratio: 3.98, CI 95%: 1.34 to 11,48; (4) similar for the genes analyzed. The consequences of these results for genetic counseling and linkage analyses are discussed.

Entities:  

Mesh:

Year:  1997        PMID: 9219008

Source DB:  PubMed          Journal:  Genet Couns        ISSN: 1015-8146


  21 in total

Review 1.  The role of magnetic resonance imaging in hypertrophic cardiomyopathy.

Authors:  Edward T D Hoey; Mohamed Elassaly; Arul Ganeshan; Richard W Watkin; Helen Simpson
Journal:  Quant Imaging Med Surg       Date:  2014-10

2.  Adrenergic stress reveals septal hypertrophy and proteasome impairment in heterozygous Mybpc3-targeted knock-in mice.

Authors:  Saskia Schlossarek; Friederike Schuermann; Birgit Geertz; Giulia Mearini; Thomas Eschenhagen; Lucie Carrier
Journal:  J Muscle Res Cell Motil       Date:  2011-11-11       Impact factor: 2.698

3.  Founder mutations in hypertrophic cardiomyopathy patients in the Netherlands.

Authors:  I Christiaans; E A Nannenberg; D Dooijes; R J E Jongbloed; M Michels; P G Postema; D Majoor-Krakauer; A van den Wijngaard; M M A M Mannens; J P van Tintelen; I M van Langen; A A M Wilde
Journal:  Neth Heart J       Date:  2010-05       Impact factor: 2.380

Review 4.  The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy.

Authors:  Lucie Carrier; Saskia Schlossarek; Monte S Willis; Thomas Eschenhagen
Journal:  Cardiovasc Res       Date:  2009-07-17       Impact factor: 10.787

Review 5.  Insights and challenges in hypertrophic cardiomyopathy, 2012.

Authors:  Srijita Sen-Chowdhry; María Teresa Tomé Esteban; William J McKenna
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2012-09-25

6.  1H- and 31P-myocardial magnetic resonance spectroscopy in non-obstructive hypertrophic cardiomyopathy patients and competitive athletes.

Authors:  Francesco Secchi; Giovanni Di Leo; Marcello Petrini; Riccardo Spairani; Marco Alì; Marco Guazzi; Francesco Sardanelli
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

Review 7.  Evolving health care through personal genomics.

Authors:  Heidi L Rehm
Journal:  Nat Rev Genet       Date:  2017-01-31       Impact factor: 53.242

Review 8.  The many faces of hypertrophic cardiomyopathy: from developmental biology to clinical practice.

Authors:  Iacopo Olivotto; Francesca Girolami; Stefano Nistri; Alessandra Rossi; Luigi Rega; Francesca Garbini; Camilla Grifoni; Franco Cecchi; Magdi H Yacoub
Journal:  J Cardiovasc Transl Res       Date:  2009-10-27       Impact factor: 4.132

9.  A new locus for autosomal dominant dilated cardiomyopathy identified on chromosome 6q12-q16.

Authors:  N Sylvius; F Tesson; C Gayet; P Charron; A Bénaïche; M Peuchmaurd; L Duboscq-Bidot; J Feingold; J S Beckmann; C Bouchier; M Komajda
Journal:  Am J Hum Genet       Date:  2000-11-20       Impact factor: 11.025

Review 10.  Gender-related differences in heart failure: beyond the "one-size-fits-all" paradigm.

Authors:  Annamaria De Bellis; Giulia De Angelis; Enrico Fabris; Antonio Cannatà; Marco Merlo; Gianfranco Sinagra
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.